Overview
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Basic Stats
The share price of Beam Therapeutics Inc. as of September 5, 2025 is $20.91 / share. This is an increase of 27.81% from the prior week. The market cap (or net worth) of Beam Therapeutics Inc. as of September 5, 2025 is $2,046.53 MM.
The Factor Analysis chart (below right) shows a view of Beam Therapeutics Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 2,046.53 MM |
| EV | 1,764.40 MM |
| Shares Out. | 97.87 MM |
| Earnings Date | |
| EPS (TTM) | -4.07 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.41 |
| Short Shares Avail. | 0.10 MM |
| Short Interest | 27.17 MM |
| Short Float | 31.23 % |
| Days to Cover | 6.55 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -13.52 % |
| Volatility (1 yr) | 0.73 |
| Beta | 1.79 |
| Sharpe Ratio (1 yr) | -0.24 |
| Sortino Ratio (1 yr) | -0.42 |
| PE Ratio | -5.13 |
| Price/Book | 1.96 |
| Price/TBV | 1.96 |
| Book/Market | 0.51 |
| EBIT/EV | -0.23 |
| EBIT(3yr avg)/EV | -0.16 |
| ROA | -0.32 |
| ROE | -0.47 |
| ROIC | -0.33 |
| CROIC | -0.01 |
| OCROIC | -0.29 |
| Implied Volatility | 74.79 % |
| Put/Call OI Ratio | 0.43 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Beam Therapeutics Inc. is $45.74. The forecasts range from a low of $20.20 to a high of $84.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Beam Therapeutics Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-20 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2022-12-13 | Citigroup | Buy | Initiate | |
| 2022-11-08 | Credit Suisse | Neutral | Maintains | |
| 2022-11-07 | SVB Leerink | Outperform | Maintains | |
| 2022-08-10 | SVB Leerink | Outperform | Maintains | |
| 2022-08-10 | Barclays | Equal-Weight | Maintains | |
| 2022-06-17 | BMO Capital | Market Perform | Initiate | |
| 2022-05-09 | SVB Leerink | Outperform | Maintains | |
| 2022-04-28 | Credit Suisse | Neutral | Initiate | |
| 2022-01-10 | SVB Leerink | Outperform | Maintains | |
| 2022-01-05 | Guggenheim | Buy | Initiate | |
| 2021-11-09 | SVB Leerink | Outperform | Maintains | |
| 2021-10-19 | SVB Leerink | Outperform | Initiate | |
| 2021-09-10 | B of A Securities | Buy | Initiate | |
| 2021-06-29 | Wedbush | Outperform | Maintains | |
| 2021-05-11 | Redburn Partners | Buy | Initiate | |
| 2021-05-04 | RBC Capital | Sector Perform | Initiate | |
| 2021-03-01 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2021-02-16 | Wells Fargo | Overweight | Initiate | |
| 2021-01-29 | JP Morgan | Overweight | Neutral | Downgrade |
| 2021-01-06 | Stifel | Hold | Initiate | |
| 2020-08-05 | William Blair | Outperform | Initiate | |
| 2020-03-02 | Wedbush | Outperform | Initiate | |
| 2020-03-02 | Jefferies | Buy | Initiate | |
| 2020-03-02 | Barclays | Overweight | Initiate | |
| 2014-04-01 | Stifel Nicolaus | Hold | Downgrade | |
| 2014-01-16 | Argus | Hold | Sell | Downgrade |
| 2014-01-15 | SunTrust Robinson Humphrey | Neutral | Downgrade | |
| 2013-11-25 | RBC Capital | Sector Perform | Initiate | |
| 2013-11-08 | ISI Group | Neutral | Initiate | |
| 2013-09-04 | Argus | Buy | Hold | Downgrade |
| 2013-05-16 | Stifel Nicolaus | Hold | Buy | Upgrade |
| 2013-05-03 | Citigroup | Neutral | Buy | Upgrade |
| 2013-03-22 | Stifel Nicolaus | Hold | Initiate | |
| 2012-11-02 | Citigroup | Neutral | Maintains | |
| 2012-10-22 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2012-08-17 | Credit Agricole | Buy | Underperform | Downgrade |
| 2012-06-22 | JP Morgan | Neutral | Initiate | |
| 2023-02-01 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-01-23 | SVB Leerink | Outperform | Maintains | |
| 2023-03-01 | Wells Fargo | Overweight | Maintains | |
| 2023-03-21 | Bernstein | Market Perform | Initiate | |
| 2023-05-11 | Citigroup | Buy | Buy | Maintains |
| 2023-05-11 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-05-11 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-12-08 | Jefferies | Buy | Hold | Downgrade |
| 2024-04-23 | Wedbush | Outperform | Outperform | Reiterate |
| 2023-08-09 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-09 | Credit Suisse | Neutral | Neutral | Maintains |
| 2023-08-09 | Citigroup | Buy | Buy | Maintains |
| 2023-09-13 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-08-29 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-10-17 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-12-15 | B of A Securities | Buy | Neutral | Downgrade |
| 2024-03-27 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-05-08 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-02-28 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-02-28 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-01-29 | JP Morgan | Neutral | Overweight | Upgrade |
| 2024-10-16 | Scotiabank | Sector Perform | Initiate | |
| 2024-09-11 | Stifel | Buy | Buy | Maintains |
| 2024-11-06 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-11-06 | Leerink Partners | Market Perform | Outperform | Upgrade |
| 2025-02-27 | Guggenheim | Buy | Buy | Reiterate |
| 2024-08-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-07 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2024-08-07 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-07 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-07-23 | HC Wainwright & Co. | Buy | Initiate | |
| 2025-05-07 | Guggenheim | Buy | Buy | Maintains |
| 2025-05-07 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-05-07 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-12-09 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-17 | Jones Trading | Hold | Initiate | |
| 2025-01-29 | Cantor Fitzgerald | Neutral | Overweight | Upgrade |
| 2025-03-28 | B of A Securities | Neutral | Buy | Upgrade |
| 2025-02-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-19 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2025-03-03 | Scotiabank | Sector Perform | Sector Perform | Maintains |
| 2025-03-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-10 | Jones Trading | Hold | Buy | Upgrade |
| 2025-03-10 | Scotiabank | Sector Perform | Sector Outperform | Upgrade |
| 2025-02-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-26 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-03-12 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-04-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-08-06 | Barclays | Equal-Weight | Equal-Weight | Maintains |
